Jan Astermark

8.0k total citations
163 papers, 5.3k citations indexed

About

Jan Astermark is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Jan Astermark has authored 163 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Hematology, 48 papers in Genetics and 35 papers in Molecular Biology. Recurrent topics in Jan Astermark's work include Hemophilia Treatment and Research (144 papers), Blood Coagulation and Thrombosis Mechanisms (56 papers) and Platelet Disorders and Treatments (46 papers). Jan Astermark is often cited by papers focused on Hemophilia Treatment and Research (144 papers), Blood Coagulation and Thrombosis Mechanisms (56 papers) and Platelet Disorders and Treatments (46 papers). Jan Astermark collaborates with scholars based in Sweden, United States and Germany. Jan Astermark's co-authors include Erik Berntorp, Johannes Oldenburg, Erik Berntorp, A. Gringeri, Sharyne Donfield, Rolf Ljung, Kathelijn Fischer, Donna DiMichele, Pia Petrini and Sam Schulman and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jan Astermark

156 papers receiving 5.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Astermark Sweden 40 5.0k 1.4k 1000 241 178 163 5.3k
Maria Elisa Mancuso Italy 34 4.0k 0.8× 1.0k 0.8× 694 0.7× 103 0.4× 243 1.4× 178 4.6k
Jerzy Windyga Poland 30 4.3k 0.9× 1.1k 0.8× 510 0.5× 187 0.8× 195 1.1× 174 4.8k
Leonard A. Valentino United States 35 2.9k 0.6× 913 0.7× 571 0.6× 80 0.3× 198 1.1× 147 3.5k
Rebecca Kruse‐Jarres United States 23 3.0k 0.6× 1.0k 0.8× 306 0.3× 123 0.5× 136 0.8× 77 3.2k
Shirley D’Sa United Kingdom 25 1.4k 0.3× 758 0.5× 469 0.5× 184 0.8× 628 3.5× 122 2.4k
Savita Rangarajan United Kingdom 29 1.9k 0.4× 438 0.3× 877 0.9× 55 0.2× 461 2.6× 102 3.0k
Magdalini Migkou Greece 27 1.5k 0.3× 400 0.3× 1.3k 1.3× 143 0.6× 1.3k 7.3× 160 2.6k
Marinus van Marwijk Kooy Netherlands 23 2.1k 0.4× 375 0.3× 843 0.8× 35 0.1× 658 3.7× 44 2.6k
Barbara Finck United States 8 1.5k 0.3× 375 0.3× 268 0.3× 267 1.1× 246 1.4× 17 3.6k
Muneer H. Abidi United States 22 1.5k 0.3× 321 0.2× 977 1.0× 150 0.6× 1.5k 8.5× 92 2.7k

Countries citing papers authored by Jan Astermark

Since Specialization
Citations

This map shows the geographic impact of Jan Astermark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Astermark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Astermark more than expected).

Fields of papers citing papers by Jan Astermark

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Astermark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Astermark. The network helps show where Jan Astermark may publish in the future.

Co-authorship network of co-authors of Jan Astermark

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Astermark. A scholar is included among the top collaborators of Jan Astermark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Astermark. Jan Astermark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Andersson, Nadine G., et al.. (2024). Primary prophylaxis implementation and long‐term joint outcomes in Swedish haemophilia A patients. Haemophilia. 30(3). 671–677.
3.
Delignat, Sandrine, Jan Astermark, H. Lévesque, et al.. (2023). The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice. Haematologica. 108(5). 1322–1334. 6 indexed citations
4.
Carlsson, Katarina Steen, Bent Winding, Jan Astermark, et al.. (2023). High use of pain, depression, and anxiety drugs in hemophilia: more than 3000 people with hemophilia in an 11-year Nordic registry study. Research and Practice in Thrombosis and Haemostasis. 7(2). 100061–100061. 4 indexed citations
5.
Baghaei, Fariba, Maria Bruzelius, Pål André Holme, et al.. (2023). No difference in quality of life between persons with severe haemophilia A and B. Haemophilia. 29(4). 987–996. 4 indexed citations
6.
Baghaei, Fariba, Maria Bruzelius, Pål André Holme, et al.. (2022). Factor IX antibodies and tolerance in hemophilia B in the Nordic countries – The impact of F9 variants and complications. Thrombosis Research. 217. 22–32. 1 indexed citations
7.
Astermark, Jan, Cihan Ay, Manuela Carvalho, et al.. (2021). New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia. Thrombosis and Haemostasis. 122(6). 905–912.
8.
Astermark, Jan, Katharina Holstein, Susan Kearney, et al.. (2021). The B‐Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia. 27(5). 802–813. 10 indexed citations
9.
Astermark, Jan. (2012). Prevention and prediction of inhibitor risk. Haemophilia. 18(s4). 38–42. 26 indexed citations
10.
Fusco, Francesca, L Scalone, Angiola Rocino, et al.. (2011). Cost of Immune Tolerance Induction in Hemophilia A Patients: Results from the ITER Study. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). 2005(26). nf52–nf52. 1 indexed citations
11.
Nilsson‐Ehle, Herman, Gunnar Birgegård, Jan Samuelsson, et al.. (2011). Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. European Journal Of Haematology. 87(3). 244–252. 49 indexed citations
12.
Berntorp, Erik, Jan Astermark, Fariba Baghaei, et al.. (2011). Treatment of haemophilia A and B and von Willebrand’s disease: summary and conclusions of a systematic review as part of a Swedish health‐technology assessment. Haemophilia. 18(2). 158–165. 28 indexed citations
13.
Astermark, Jan, et al.. (2010). Bone density and health-related quality of life in adult patients with severe haemophilia. Haemophilia. 17(2). 304–311. 28 indexed citations
14.
Astermark, Jan, et al.. (2010). Mild haemophilia in Sweden. Haemophilia. 16. 90–90. 3 indexed citations
15.
Collins, P., Jan Astermark, Sven Björkman, et al.. (2008). The importance of maintaining FVIII through levels above 1% during prophylactic treatment of hemophilia A: using license study databases to answer key medical questions. Lund University Publications (Lund University). 3 indexed citations
16.
Collins, P., Victor S. Blanchette, Kathelijn Fischer, et al.. (2008). Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostasis. 7(3). 413–420. 262 indexed citations
17.
Berntorp, Erik, Jan Astermark, V. Blanchette, et al.. (2006). Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 12(s6). 1–7. 82 indexed citations
18.
Astermark, Jan, Johannes Oldenburg, Jonas Carlson, et al.. (2006). Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 108(12). 3739–3745. 160 indexed citations
19.
Astermark, Jan, et al.. (2001). Comparison of two prophylactic regimens for severe hemophilia: Intermediate dose versus high dose.. Data Archiving and Networked Services (DANS). 1 indexed citations
20.
Berntorp, Erik, et al.. (2000). Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.. Lund University Publications (Lund University). 85(10 Suppl). 48–1. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Elisa Mancuso Breakdown of academic impact, for papers by Jerzy Windyga Breakdown of academic impact, for papers by Leonard A. Valentino Breakdown of academic impact, for papers by Rebecca Kruse‐Jarres Breakdown of academic impact, for papers by Shirley D’Sa Breakdown of academic impact, for papers by Savita Rangarajan Breakdown of academic impact, for papers by Magdalini Migkou Breakdown of academic impact, for papers by Marinus van Marwijk Kooy Breakdown of academic impact, for papers by Barbara Finck Breakdown of academic impact, for papers by Muneer H. Abidi
Rankless by CCL
2026